Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Go back to Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia| ALKERMES (NASDAQ: ALKS) | Delayed: 46.02 +1.03 (2.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.99 | 52 Week High | $80.71 | |||
| Open | $45.40 | 52 Week Low | $27.14 | |||
| Day High | $46.63 | P/E | 354.00 | |||
| Day Low | $45.01 | EPS | $0.13 | |||
| Volume | 3,226,993 | |||||
